文献速递妇科肿瘤

尼拉帕利维持治疗铂敏感复发性卵巢癌的真实世界安全性与有效性:西班牙扩大可及项目中的GEICO回顾性观察研究

Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme.
PubMed 文献 · Eur J Cancer · 2022-12-29

该回顾性观察研究纳入西班牙尼拉帕利扩大可及项目中316例铂敏感复发性高级别浆液性卵巢癌患者,80%为BRCA野生型,66%接受个体化起始剂量。中位无进展生存期为8.6个月(95%CI 7.6-10.0),1年和2年总生存率分别为86%(95%CI 81-89%)和65%(95%CI 59-70%)。个体化起始剂量较固定起始剂量剂量中断、减量、血液学毒性和乏力/疲劳更少见,但无进展生存期相似。

要点

  • 316例患者中80%为BRCA野生型,66%接受个体化起始剂量,中位尼拉帕利治疗时长7.8个月。
  • 中位无进展生存期8.6个月(95%CI 7.6-10.0),1年和2年总生存率分别为86%和65%。
  • 个体化起始剂量较固定起始剂量毒性更少,但无进展生存期相似。

核心结论

  • 该大型真实世界数据集的结果与III期试验一致,为尼拉帕利维持治疗铂敏感复发性卵巢癌的耐受性和活性提供了令人安心的证据。

研究设计与样本

  • 西班牙尼拉帕利扩大可及项目中的回顾性观察研究,纳入316例铂敏感复发性高级别浆液性卵巢癌女性。
  • 入组患者既往接受≥2线含铂治疗,倒数第二线含铂治疗后仍为铂敏感,且对最近一次含铂治疗有响应。
  • 尼拉帕利剂量由治疗医生决定:300 mg/日固定起始剂量或根据基线体重和血小板计数个体化起始剂量(ISD)。

主要发现

  • 316例可评估患者中80%为BRCA野生型肿瘤,66%接受个体化起始剂量。
  • 中位尼拉帕利治疗时长为7.8个月,最常见不良事件通常发生在开始尼拉帕利后3个月内。
  • 中位无进展生存期为8.6个月(95%CI 7.6-10.0)。
  • 1年和2年总生存率分别为86%(95%CI 81-89%)和65%(95%CI 59-70%)。
  • 个体化起始剂量较固定起始剂量剂量中断、剂量减少、血液学毒性和乏力/疲劳更少见,但无论剂量策略如何无进展生存期相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: To describe patient characteristics, effectiveness and safety in a real-world population treated with niraparib in the Spanish expanded-access programme. PATIENTS AND METHODS: This retrospective observational study included women with platinum-sensitive recurrent high-grade serous ovarian cancer who received maintenance niraparib within the Spanish niraparib expanded-access programme. Eligible patients had received ≥2 previous lines of platinum-containing therapy, remained platinum-sensitive after the penultimate line of platinum and had responded to the most recent platinum-containing therapy. Niraparib dosing was at the treating physician's discretion (300 mg/day fixed starting dose or individualised starting dose [ISD] according to baseline body weight and platelet count). Safety, impact of dose adjustments, patient characteristics and effectiveness were analysed using data extracted from medical records. RESULTS: Among 316 eligible patients, 80% had BRCA wild-type tumours and 66% received an ISD. Median niraparib duration was 7.8 months. The most common adverse events typically occurred within 3 months of starting niraparib. Median progression-free survival was 8.6 (95% confidence interval [CI] 7.6-10.0) months. One- and 2-year overall survival rates were 86% (95% CI 81-89%) and 65% (95% CI 59-70%), respectively. Dose interruptions, dose reductions, haematological toxicities and asthenia/fatigue were less common with ISD than fixed starting dose niraparib, but progression-free survival was similar irrespective of dosing strategy. Subsequent therapy included platinum in 71% of patients who received further treatment. CONCLUSION: Outcomes in this large real-world dataset of niraparib-treated patients are consistent with phase III trials, providing reassuring evidence of the tolerability and activity of niraparib maintenance therapy for platinum-sensitive recurrent ovarian cancer. GOV REGISTRATION: NCT04546373.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Cueva JF, Palacio I, Churruca C, et al. Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme. Eur J Cancer. 2022. PMID: 36706655. doi:10.1016/j.ejca.2022.12.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。